Navigation Links
Journal of Alzheimer's Disease special issue explores multifaceted aspects of AD
Date:11/15/2007

Amsterdam, November 15, 2007 A recently published special issue of the Journal of Alzheimer's Disease contains the contributions from experts in the field of aging, dementia and Alzheimers disease, who attended the Fourth Annual Meeting on Brain aging and Dementia: From successful aging to severe dementia. Held in Perugia in October 2006 under the auspices of the Italian Psychogeriatric Association, a member of the International Psychogeriatric Association, the meeting celebrates the centenary of Alzheimers first description of the disease.

The articles cover several topics on AD: sociological, epidemiological, clinical and biological aspects offer a wide overview on this multifaceted disease.

Robert Binstock, from Case Western Reserve University, Cleveland (USA), reports some reflections on the ethical, moral and policy challenges for healthcare professionals and politicians due to the aging of industrialized nations. This social phenomenon is associated with an enhanced demand for both acute and long-term healthcare for the elderly that will increasingly strain economic resources.

Laura Fratiglioni and Hui-Xin Wang, from the Karolinska Institute of Stockholm (Sweden), review the concept of brain reserve that refers to the ability to tolerate the age-related changes and disease-related pathology in the brain without developing clear clinical symptoms. Epidemiological studies indicate that brain reserve is related to a number of aspects including high education, adult-life occupational work complexity, as well as a mentally and socially integrated lifestyle.

Guest Editor Patrizia Mecocci and colleagues from the Italian University of Perugia (Elena Mariani) and University of Palermo (Roberto Monastero) review the most recent aspects related to the epidemiological, clinical, neuropathological, neuroimaging, biochemical and therapeutic aspects of Mild Cognitive Impairment, a nosological entity proposed as an intermediate state between normal aging and dementia, with specific attention to possible markers of conversion to dementia.

Ezio Giacobini and Robert Becker from the University of Geneva (Switzerland) expand on possible treatments of AD that should modify the course of the pathological processes at the basis of this disease. Several active and passive vaccines against amyloid- humanized antibody, drugs aiming to reduce tau phosphorylation (GSK3 inhibitors), anti-amyloid-aggregation and anti-APO-E molecules are considered, while the developments of gamma-and beta-secretase inhibitors, due to intrinsic difficulties, seem to have not yet reached the clinical stages.

Clive Ballard and his colleagues Susanne Sorensen and Samantha Sharp from Kings College, London (UK) give a brief overview of the clinical effectiveness of cholinesterase inhibitors for the treatment of Alzheimer's disease, discuss in detail the NICE appraisal of these treatments in the UK as a example of an attempt at a standardized evaluation of cost-effectiveness and argue a proposed way forward to achieve a unified and consistent approach to the assessment of cost-effectiveness for anti-dementia therapies.

Allan Butterfield and Rukhsana Sultana from the University of Kentucky, Lexington (USA) write of their studies on oxidative stress in AD and MCI brain indexed by protein oxidation and lipid peroxidation and summarize findings of oxidatively modified proteins using redox proteomics approach in AD and MCI brain aimed to investigate the mechanism that may be involved in their pathogenesis as well as in terms of MCI progression to AD.

Alessandro Serretti, Paolo Olgiati and Diana De Ronchi, from the University of Bologna (Italy) discuss the genetics of Alzheimer's disease, focusing on the sporadic form in which most genes, related to the amyloid- deposition, oxidative stress and inflammatory response are involved. They report that genetic mechanisms are also involved in expression of depression and psychotic symptoms that occur in a large proportion of AD patients and in the therapeutic effect of drugs currently used.

Cristina Lanni and colleagues from the University of Pavia (Italy) discuss the methodologies that have been used to identify an altered conformational status of p53 in fibroblasts of AD patients. They explain that this alteration may be related to exposure to low amounts of soluble A peptide, not resulting in cytotoxic effects. On this basis, they hypothesize that unfolded p53 could be considered as an agent participating in the early pathogenesis and as a specific marker of the early stage of AD.

Finally, Eugenio Mocchegiani and Marco Malavolta from INRCA (National Institute of Research and Cure for the Elderly) of Ancona (Italy) write about the role of zinc homeostasis in different conditions of brain dysfunction, including brain inflammatory status, aging brain and neurodegeneration They also discuss the role played by metallothioneins (which regulate the intracellular free zinc ions) and 2 macroglobulin (a zinc-binding protein) in aging and AD.


'/>"/>

Contact: Astrid Engelen
a.engelen@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. News briefs from the journal Chest, August 2007
2. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
3. Elsevier launches new journal: Stem Cell Research
4. Elsevier announces new journal on inflammatory bowel diseases
5. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
6. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
7. Good Clinical Practice Journal Awards: Winners Announced
8. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
9. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
10. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
11. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: